Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Effectiveness of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria and Adverse Birth Outcomes in Pregnant Women.

Mlugu EM, Minzi O, Asghar M, Färnert A, Kamuhabwa AAR, Aklillu E.

Pathogens. 2020 Mar 11;9(3). pii: E207. doi: 10.3390/pathogens9030207.

2.

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.

Mugusi S, Habtewold A, Ngaimisi E, Amogne W, Yimer G, Minzi O, Makonnen E, Sudfeld C, Burhenne J, Aklillu E.

Front Pharmacol. 2020 Feb 7;11:26. doi: 10.3389/fphar.2020.00026. eCollection 2020.

3.

Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya.

Nyamu DG, Guantai AN, Osanjo GO, Godman B, Aklillu E.

Expert Rev Cardiovasc Ther. 2020 Mar 2:1-9. doi: 10.1080/14779072.2020.1734452. [Epub ahead of print]

PMID:
32090626
4.

Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.

Kilonzi M, Minzi O, Mutagonda R, Baraka V, Sasi P, Aklillu E, Kamuhabwa A.

Malar J. 2020 Feb 11;19(1):66. doi: 10.1186/s12936-020-3150-y.

5.

Prevalence and correlates of intestinal schistosomiasis infection among school-aged children in North-Western Tanzania.

Mnkugwe RH, Minzi OS, Kinung'hi SM, Kamuhabwa AA, Aklillu E.

PLoS One. 2020 Feb 5;15(2):e0228770. doi: 10.1371/journal.pone.0228770. eCollection 2020.

6.

Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.

Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, Oluka M, Guantai A, Bergman U, van Puijenbroek E, Gurumurthy P, Aklillu E.

Drug Saf. 2020 Jan 9. doi: 10.1007/s40264-019-00898-z. [Epub ahead of print]

PMID:
31919794
7.

Efficacy and Safety of Praziquantel for Treatment of Schistosoma mansoni Infection among School Children in Tanzania.

Mnkugwe RH, Minzi OS, Kinung'hi SM, Kamuhabwa AA, Aklillu E.

Pathogens. 2019 Dec 27;9(1). pii: E28. doi: 10.3390/pathogens9010028.

8.

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.

Mukonzo JK, Kengo A, Kutesa B, Nanzigu S, Pohanka A, McHugh TD, Zumla A, Aklillu E.

Trans R Soc Trop Med Hyg. 2020 Feb 7;114(2):107-114. doi: 10.1093/trstmh/trz108.

PMID:
31789383
9.

Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations.

Mutagonda RF, Minzi OMS, Massawe SN, Asghar M, Färnert A, Kamuhabwa AAR, Aklillu E.

Drug Metab Dispos. 2019 Dec;47(12):1415-1424. doi: 10.1124/dmd.119.088062.

PMID:
31744845
10.

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study.

Tadesse BT, Chala A, Mukonzo J, Chaka TE, Tadesse S, Makonnen E, Brumme ZL, Brumme CJ, Aklillu E.

Pathogens. 2019 Sep 24;8(4). pii: E161. doi: 10.3390/pathogens8040161.

11.

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Fotoohi A, Aseffa A, Howe R, Aklillu E.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1353. doi: 10.3390/cancers11091353.

12.

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia.

Tadesse BT, Tsai O, Chala A, Chaka TE, Eromo T, Lapointe HR, Baraki B, Shahid A, Tadesse S, Makonnen E, Brumme ZL, Aklillu E, Brumme CJ.

Viruses. 2019 Sep 19;11(9). pii: E877. doi: 10.3390/v11090877.

13.

Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region.

Mikomangwa WP, Oms M, Aklillu E, Kamuhabwa AAR.

BMC Pregnancy Childbirth. 2019 Jul 8;19(1):236. doi: 10.1186/s12884-019-2397-1.

14.

CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M, Aseffa A, Howe R, Fotoohi A, Hassan M, Aklillu E.

Front Pharmacol. 2019 May 14;10:481. doi: 10.3389/fphar.2019.00481. eCollection 2019.

15.

Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.

Mukonzo J, Aklillu E, Marconi V, Schinazi RF.

Int J Infect Dis. 2019 Jun;83:98-101. doi: 10.1016/j.ijid.2019.04.009. Epub 2019 Apr 13.

16.
17.

HIV and cART-Associated Dyslipidemia Among HIV-Infected Children.

Tadesse BT, Foster BA, Chala A, Chaka TE, Bizuayehu T, Ayalew F, H/Meskel G, Tadesse S, Jerene D, Makonnen E, Aklillu E.

J Clin Med. 2019 Mar 28;8(4). pii: E430. doi: 10.3390/jcm8040430.

19.

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia.

Ahmed JH, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, Tigeneh W, Aseffa A, Howe R, Aklillu E.

Nutrients. 2019 Jan 29;11(2). pii: E289. doi: 10.3390/nu11020289.

20.

Conference report: pharmacogenomics in special populations at WCP2018.

Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA.

Br J Clin Pharmacol. 2019 Mar;85(3):467-475. doi: 10.1111/bcp.13828. Epub 2019 Jan 24.

21.

Cigarette smoking and heavy coffee consumption affecting response to olanzapine: the role of genetic polymorphism.

Djordjevic N, Radmanovic B, Cukic J, Baskic D, Djukic-Dejanovic S, Milovanovic D, Aklillu E.

World J Biol Psychiatry. 2018 Dec 4:1-53. doi: 10.1080/15622975.2018.1548779. [Epub ahead of print]

PMID:
30513034
22.

Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study.

Tadesse BT, Foster BA, Kabeta A, Ayalew F, H/Meskel G, Jerene D, Makonnen E, Aklillu E.

HIV Med. 2019 Feb;20(2):147-156. doi: 10.1111/hiv.12693. Epub 2018 Nov 26.

PMID:
30474906
23.

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E.

Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.

24.

Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.

Bedada W, de Andrés F, Engidawork E, Hussein J, LLerena A, Aklillu E.

Sci Rep. 2018 Aug 24;8(1):12726. doi: 10.1038/s41598-018-31191-1.

25.

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.

Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.

26.

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N.

Eur J Clin Pharmacol. 2018 Jul;74(7):903-911. doi: 10.1007/s00228-018-2448-y. Epub 2018 Mar 27.

27.

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Tadesse BT, Kinloch NN, Baraki B, Lapointe HR, Cobarrubias KD, Brockman MA, Brumme CJ, Foster BA, Jerene D, Makonnen E, Aklillu E, Brumme ZL.

Viruses. 2018 Feb 1;10(2). pii: E60. doi: 10.3390/v10020060.

28.

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.

Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, Färnert A, Aklillu E.

Malar J. 2017 Jul 3;16(1):267. doi: 10.1186/s12936-017-1914-9.

29.

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.

30.

Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Petros Z, Lee MT, Takahashi A, Zhang Y, Yimer G, Habtewold A, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

OMICS. 2017 Apr;21(4):207-216. doi: 10.1089/omi.2017.0019.

31.

HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.

Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E.

Front Pharmacol. 2017 Feb 27;8:90. doi: 10.3389/fphar.2017.00090. eCollection 2017.

32.

Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Petros Z, Makonnen E, Aklillu E.

OMICS. 2017 Mar;21(3):123-131. doi: 10.1089/omi.2017.0006. Epub 2017 Feb 16.

33.

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.

Petros Z, Lee MM, Takahashi A, Zhang Y, Yimer G, Habtewold A, Amogne W, Aderaye G, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

BMC Genomics. 2016 Sep 26;17(1):755.

34.

SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.

Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, Hoffmann MM, Weiss J.

OMICS. 2016 Sep;20(9):538-45. doi: 10.1089/omi.2016.0119.

PMID:
27631193
35.

Conference Report: First Pharmacogenetics and Precision Medicine Conference in Africa (April 7-9, 2016, Cape Town, South Africa).

Dandara C, Suarez-Kurtz G, Aklillu E.

OMICS. 2016 Sep;20(9):496-7. doi: 10.1089/omi.2016.0128. No abstract available.

PMID:
27631188
36.

Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking.

Dandara C, Endrenyi L, Kolker E, Hekim N, Steuten LM, Güngör K, Aklillu E, Özdemir V.

OMICS. 2016 Sep;20(9):493-5. doi: 10.1089/omi.2016.0129. No abstract available.

PMID:
27631187
37.

High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.

Desta K, Woldeamanuel Y, Azazh A, Mohammod H, Desalegn D, Shimelis D, Gulilat D, Lamisso B, Makonnen E, Worku A, Mannerqvist K, Struwe J, Aspevall O, Aklillu E.

PLoS One. 2016 Aug 30;11(8):e0161685. doi: 10.1371/journal.pone.0161685. eCollection 2016.

38.

Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Medicine (Baltimore). 2016 Aug;95(34):e4631. doi: 10.1097/MD.0000000000004631.

39.

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, Aklillu E, Makonnen E, Aderaye G, Roach J, Fier I, Kampf C, Göpfert J, Perazzo H, Poynard T, Stephens C, Andrade RJ, Lucena MI, Arber N, Uhlén M, Watkins PB, Schwenk JM, Nilsson P, Schuppe-Koistinen I.

Liver Int. 2017 Jan;37(1):132-140. doi: 10.1111/liv.13174. Epub 2016 Jun 22.

40.

Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women.

Mutagonda RF, Kamuhabwa AA, Minzi OM, Massawe SN, Maganda BA, Aklillu E.

Malar J. 2016 May 13;15(1):278. doi: 10.1186/s12936-016-1327-1.

41.

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J.

J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29.

PMID:
27125860
42.

An Open Letter in Support of Transformative Biotechnology and Social Innovation: SANKO University Innovation Summit in Medicine and Integrative Biology, Gaziantep, Turkey, May 5-7, 2016.

Saygılı Eİ, Abou-Zeid AH, Akkın SM, Aklillu E, Barlas İÖ, Borda-Rodriguez A, Boschele FA, Çetin Z, Coşkun E, Coşkun Y, Dağlı G, Dai TU, Dandara C, Dereli T, Elbeyli L, Endrenyi L, Eyigün CP, Georgakilas A, Günbulut B, Güngör K, Güzelbey A, Hekim C, Huzair F, Kimyon S, Karakaş Ü, Lin B, LLerena A, Masimirembwa C, McNally R, Mete A, Sancar P, Srivastava S, Steuten LM, Tanrıöver O, Tyfield D, Töre Vİ, Vuruşkan D, Wang W, Warnich L, Wonkam A, Yıldırım YZ, Yılmaz İ, Sınav A, Hekim N.

OMICS. 2016 Apr;20(4):259-62. doi: 10.1089/omi.2016.0038. No abstract available.

PMID:
27093110
43.

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.

Mukonzo JK, Bisaso RK, Ogwal-Okeng J, Gustafsson LL, Owen JS, Aklillu E.

Pharmacogenomics. 2016 Apr;17(6):603-13. doi: 10.2217/pgs.16.7. Epub 2016 Apr 5.

PMID:
27045425
44.

miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.

Ekström L, Skilving I, Ovesjö ML, Aklillu E, Nylén H, Rane A, Diczfalusy U, Björkhem-Bergman L.

Pharmacol Res Perspect. 2015 Oct 27;3(6):e00192. doi: 10.1002/prp2.192. eCollection 2015 Dec.

45.
46.

The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.

Bedada W, de Andrés F, Engidawork E, Pohanka A, Beck O, Bertilsson L, Llerena A, Aklillu E.

J Clin Psychopharmacol. 2015 Dec;35(6):694-9. doi: 10.1097/JCP.0000000000000413.

PMID:
26444948
47.

Towards host-directed therapies for tuberculosis.

Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS.

Nat Rev Drug Discov. 2015 Aug;14(8):511-2. doi: 10.1038/nrd4696. Epub 2015 Jul 17.

PMID:
26184493
48.

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, Thummel KE, Schuetz EG.

Drug Metab Dispos. 2015 Aug;43(8):1226-35. doi: 10.1124/dmd.115.064428. Epub 2015 May 28.

49.

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.

Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, Eliasson E, Aklillu E.

OMICS. 2015 Jun;19(6):346-53. doi: 10.1089/omi.2015.0022. Epub 2015 May 15.

PMID:
25977991
50.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.

Supplemental Content

Loading ...
Support Center